Regeneron Pharmaceuticals Inc
XBER:RGO

Watchlist Manager
Regeneron Pharmaceuticals Inc Logo
Regeneron Pharmaceuticals Inc
XBER:RGO
Watchlist
Price: 128.94 EUR 0.71% Market Closed
Market Cap: 13.9B EUR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

RGO price has not been updated for more than 10 years. This may indicate that the stock has been delisted.

The Relative Value of one RGO stock under the Base Case scenario is 141.92 EUR. Compared to the current market price of 128.94 EUR, Regeneron Pharmaceuticals Inc is Undervalued by 9%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

RGO Relative Value
Base Case
141.92 EUR
Undervaluation 9%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

4.2
P/S
P/S
Price to Sales
4.2
vs History
92
vs Industry
60
Median 3Y
6.5
Median 5Y
6.1
Industry
7.5
Forward
4.3
More Details
13.3
P/E
P/E
Price to Earnings
13.3
vs History
68
vs Industry
9
Median 3Y
19.2
Median 5Y
17.4
Industry
24.2
Forward
15.2
More Details
12.6
P/OCF
P/OCF
Price to OCF
12.6
vs History
77
vs Industry
11
Median 3Y
17
Median 5Y
17.7
Industry
20.5
More Details
16.8
P/FCFE
P/FCFE
Price to FCFE
16.8
vs History
66
vs Industry
9
Median 3Y
24.9
Median 5Y
21.1
Industry
22.4
More Details
2
P/B
P/B
Price to Book Value
2
vs History
95
vs Industry
36
Median 3Y
3.5
Median 5Y
3.7
Industry
2.9
More Details
3.8
EV/S
EV/S
Enterprise Value to Sales
3.8
vs History
93
vs Industry
59
Median 3Y
6
Median 5Y
5.7
Industry
8
Forward
4
More Details
4.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
4.4
vs History
93
vs Industry
60
Median 3Y
6.9
Median 5Y
6.6
Industry
10.2
More Details
11.9
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
11.9
vs History
60
vs Industry
11
Median 3Y
15
Median 5Y
13.4
Industry
5.1
Forward
12
More Details
13.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
13.5
vs History
57
vs Industry
10
Median 3Y
16.3
Median 5Y
14.9
Industry
5.3
Forward
12.8
More Details
11.5
EV/OCF
EV/OCF
Enterprise Value to OCF
11.5
vs History
77
vs Industry
13
Median 3Y
15.6
Median 5Y
15.9
Industry
5.8
More Details
15.4
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
15.4
vs History
76
vs Industry
9
Median 3Y
21.9
Median 5Y
23.1
Industry
4
More Details
1.8
EV/IC
EV/IC
Enterprise Value to IC
1.8
vs History
95
vs Industry
26
Median 3Y
3.8
Median 5Y
3.8
Industry
5.1
More Details

Multiples Across Competitors

RGO Competitors Multiples
Regeneron Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Regeneron Pharmaceuticals Inc
XBER:RGO
59.4B EUR 4.2 13.3 11.9 13.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 980 524.7 -161 504.4 -196 117.9 -193 879.9
US
Abbvie Inc
NYSE:ABBV
355.8B USD 6.1 95.6 15.8 22.9
US
Amgen Inc
NASDAQ:AMGN
155.5B USD 4.5 23.5 18.4 18.4
US
Gilead Sciences Inc
NASDAQ:GILD
149.1B USD 5.2 23.6 11 15.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 073.2 -529 -576.1 -560.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
101.7B USD 8.9 27.9 20.6 21.5
AU
CSL Ltd
ASX:CSL
130.5B AUD 5.6 31 19 23.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
56.8B USD 23.1 -178.1 -444.8 -305.3
US
Seagen Inc
F:SGT
39.3B EUR 20 -61.2 -66 -59.6
NL
argenx SE
XBRU:ARGX
33.6B EUR 12.9 30.6 72.3 75.7
P/S Multiple
Revenue Growth P/S to Growth
US
Regeneron Pharmaceuticals Inc
XBER:RGO
Average P/S: 3 089 335.3
4.2
4%
1
FR
Pharnext SCA
OTC:PNEXF
33 980 524.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.1
8%
0.8
US
Amgen Inc
NASDAQ:AMGN
4.5
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
E
Epizyme Inc
F:EPE
2 073.2
N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
8.9
10%
0.9
AU
CSL Ltd
ASX:CSL
5.6
7%
0.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
23.1
31%
0.7
US
S
Seagen Inc
F:SGT
20
30%
0.7
NL
argenx SE
XBRU:ARGX
12.9
40%
0.3
P/E Multiple
Earnings Growth PEG
US
Regeneron Pharmaceuticals Inc
XBER:RGO
Average P/E: 35.1
13.3
7%
1.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 504.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
95.6
88%
1.1
US
Amgen Inc
NASDAQ:AMGN
23.5
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
23.6
189%
0.1
US
E
Epizyme Inc
F:EPE
Negative Multiple: -529 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.9
N/A N/A
AU
CSL Ltd
ASX:CSL
31
16%
1.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -178.1 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.2 N/A N/A
NL
argenx SE
XBRU:ARGX
30.6
28%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Regeneron Pharmaceuticals Inc
XBER:RGO
Average EV/EBITDA: 24.1
11.9
9%
1.3
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 117.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.8
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
18.4
10%
1.8
US
Gilead Sciences Inc
NASDAQ:GILD
11
6%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -576.1 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20.6
17%
1.2
AU
CSL Ltd
ASX:CSL
19
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -444.8 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -66 N/A N/A
NL
argenx SE
XBRU:ARGX
72.3
727%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Regeneron Pharmaceuticals Inc
XBER:RGO
Average EV/EBIT: 27.3
13.5
10%
1.3
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 879.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.9
28%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.4
19%
1
US
Gilead Sciences Inc
NASDAQ:GILD
15.1
12%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -560.7 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.5
17%
1.3
AU
CSL Ltd
ASX:CSL
23.7
14%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -305.3 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.6 N/A N/A
NL
argenx SE
XBRU:ARGX
75.7
N/A N/A

See Also

Summary
RGO intrinsic value, competitors valuation, and company profile.
DCF Valuation
RGO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RGO stock valuation using valuation multiples.
Wall Street Estimates
RGO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RGO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 274,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.